MA27382A1 - DERIVES D'INDOLE OU DE BENZIMIDAZOLE POUR MODULER L'IkB KINASE - Google Patents

DERIVES D'INDOLE OU DE BENZIMIDAZOLE POUR MODULER L'IkB KINASE

Info

Publication number: MA27382A1
Authority: MA; Morocco
Prior art keywords: indole; modulating; benzimidazole derivatives; ikb kinase; ikb
Prior art date: 2002-08-17

Application number

MA28106A

Other languages

English (en)

Inventor

Olaf Ritzeler

Gerhard Jaehne

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-17

Filing date

2005-02-15

Publication date

2005-06-01

2005-02-15 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2005-06-01 Publication of MA27382A1 publication Critical patent/MA27382A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)

MA28106A 2002-08-17 2005-02-15 DERIVES D'INDOLE OU DE BENZIMIDAZOLE POUR MODULER L'IkB KINASE MA27382A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10237722A DE10237722A1 (de)	2002-08-17	2002-08-17	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Publications (1)

Publication Number	Publication Date
MA27382A1 true MA27382A1 (fr)	2005-06-01

Family

ID=31968974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA28106A MA27382A1 (fr)	2002-08-17	2005-02-15	DERIVES D'INDOLE OU DE BENZIMIDAZOLE POUR MODULER L'IkB KINASE

Country Status (42)

Country	Link
US (2)	US7285560B2 (fr)
EP (2)	EP2233483B1 (fr)
JP (1)	JP4504812B2 (fr)
KR (1)	KR101162046B1 (fr)
CN (1)	CN1314683C (fr)
AR (1)	AR040975A1 (fr)
AT (2)	ATE557018T1 (fr)
AU (1)	AU2003263196B2 (fr)
BR (1)	BR0313562A (fr)
CA (1)	CA2498559C (fr)
CO (1)	CO5690586A2 (fr)
CR (1)	CR7668A (fr)
CY (2)	CY1111692T1 (fr)
DE (2)	DE10237722A1 (fr)
DK (2)	DK2233483T3 (fr)
EC (1)	ECSP055612A (fr)
ES (2)	ES2358795T3 (fr)
HN (1)	HN2003000249A (fr)
HR (1)	HRP20050042B1 (fr)
IL (1)	IL166785A0 (fr)
JO (1)	JO2764B1 (fr)
MA (1)	MA27382A1 (fr)
ME (1)	MEP60608A (fr)
MX (1)	MXPA05001314A (fr)
MY (1)	MY140074A (fr)
NO (1)	NO330981B1 (fr)
NZ (1)	NZ538296A (fr)
OA (1)	OA12908A (fr)
PA (1)	PA8580501A1 (fr)
PE (1)	PE20040893A1 (fr)
PL (1)	PL374229A1 (fr)
PT (2)	PT2233483E (fr)
RS (1)	RS51902B (fr)
RU (1)	RU2318820C2 (fr)
SI (2)	SI2233483T1 (fr)
SV (1)	SV2004001599A (fr)
TN (1)	TNSN05045A1 (fr)
TW (1)	TWI290552B (fr)
UA (1)	UA78591C2 (fr)
UY (1)	UY27941A1 (fr)
WO (1)	WO2004022553A1 (fr)
ZA (1)	ZA200500322B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19951360A1 (de) *	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
DE10237723A1 (de) *	2002-08-17	2004-07-08	Aventis Pharma Deutschland Gmbh	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
HRP20050696B1 (en)	2003-01-14	2008-10-31	Arena Pharmaceuticals Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CA2566213A1 (fr) *	2004-05-12	2005-12-11	Aventis Pharmaceuticals Inc.	2-{[2-(2-methylamino-pyrimidine-4-yl)-1h-indole-5-carbonyle]-amine}-3-(phenylpyridine-2-yl-amine)-acide propionique substantiellement pur comme inhibiteur de kinase ikb
AR050253A1 (es)	2004-06-24	2006-10-11	Smithkline Beecham Corp	Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
DE102004033406A1 (de) *	2004-07-10	2006-02-16	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
TW200626142A (en)	2004-09-21	2006-08-01	Glaxo Group Ltd	Chemical compounds
DOP2006000010A (es) *	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
AR053114A1 (es) *	2005-01-12	2007-04-25	Aventis Pharma Inc	Sal monopotasica del acido 2-{[2-(-2-metilamino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(fenilpiridin-2-il-amino)-propionico,inhibidora de ikk-2 quinasa
US20070142417A1 (en) *	2005-05-11	2007-06-21	Aventis Pharmaceuticals Inc	Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de)	2005-06-01	2006-12-07	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
TWI380973B (zh)	2005-06-30	2013-01-01	Smithkline Beecham Corp	化合物
US8088928B2 (en) *	2005-08-04	2012-01-03	Sirtris Pharmaceuticals, Inc.	Sirtuin modulating compounds
US7855289B2 (en) *	2005-08-04	2010-12-21	Sirtris Pharmaceuticals, Inc.	Sirtuin modulating compounds
AU2006278504B2 (en)	2005-08-04	2013-01-17	Sirtris Pharmaceuticals, Inc.	Imidazopyridine derivatives as sirtuin modulating agents
US8093401B2 (en) *	2005-08-04	2012-01-10	Sirtris Pharmaceuticals, Inc.	Sirtuin modulating compounds
EP2266561A3 (fr)	2005-09-07	2011-05-18	Merck Serono S.A.	Inhibiteurs de l'IKK pour le traitement de l'endométriose
JP2009001495A (ja) *	2005-10-13	2009-01-08	Taisho Pharmaceutical Co Ltd	２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
EP2061767B1 (fr)	2006-08-08	2014-12-17	Sanofi	Imidazolidin-2,4-diones arylaminoaryl-alkyl-substituées, procédé de fabrication, médicaments les contenant et leur utilisation
AR065804A1 (es)	2007-03-23	2009-07-01	Smithkline Beecham Corp	Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CL2008001822A1 (es) *	2007-06-20	2009-03-13	Sirtris Pharmaceuticals Inc	Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
RU2477282C2 (ru) *	2007-08-17	2013-03-10	Эл Джи Лайф Сайенсиз Лтд.	Соединения индола в качестве ингибиторов клеточного некроза
AU2008319267A1 (en) *	2007-11-01	2009-05-07	Sirtris Pharmaceuticals, Inc.	Amide derivatives as sirtuin modulators
EP2217606A1 (fr) *	2007-11-08	2010-08-18	Sirtris Pharmaceuticals, Inc.	Thiazolopyridines solubilisées
US8470841B2 (en)	2008-07-09	2013-06-25	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (fr)	2008-12-08	2010-06-17	Sanofi-Aventis	Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
CN102388054B (zh)	2008-12-19	2015-03-04	西特里斯药业公司	噻唑并吡啶沉默调节蛋白调节剂的化合物
KR20130130875A (ko) *	2009-02-27	2013-12-02	이난타 파마슈티칼스, 인코포레이티드	Ｃ형 간염 바이러스 억제제
US8354539B2 (en)	2009-03-10	2013-01-15	Glaxo Group Limited	Indole derivatives as IKK2 inhibitors
CN102482312A (zh)	2009-08-26	2012-05-30	赛诺菲	新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
SG182610A1 (en)	2010-01-27	2012-08-30	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
AU2010351938B2 (en) *	2010-04-27	2014-10-30	Hutchison Medipharma Limited	Pyrimidinyl indole compounds
EP2582709B1 (fr)	2010-06-18	2018-01-24	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CA2807979A1 (fr)	2010-08-12	2012-02-16	Sanofi	Procede pour la preparation de formes enantiomeres de derives d'acide 2,3-diaminopropionique
MX2013003184A (es)	2010-09-22	2013-06-07	Arena Pharm Inc	Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
JP5790440B2 (ja) *	2010-12-01	2015-10-07	住友化学株式会社	ピリミジン化合物およびその有害生物防除用途
EP2683705B1 (fr)	2011-03-08	2015-04-22	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683699B1 (fr)	2011-03-08	2015-06-24	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683703B1 (fr)	2011-03-08	2015-05-27	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120053A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683702B1 (fr)	2011-03-08	2014-12-24	Sanofi	Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
WO2012120056A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120051A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en)	2011-03-08	2014-12-02	Sanofi	Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
PT3009431T (pt) *	2011-07-27	2017-12-26	Astrazeneca Ab	Compostos de 2-(2,4,5-anilino-substituídos)pirimidina como moduladores úteis do egfr para o tratamento do cancro
ME02908B (fr) *	2011-08-25	2018-10-20	Medicines For Malaria Venture Mmv	2-alkyl-1-oxo-n-phényl-3-hétéroaryl-1,2,3,4-tétrahydroisoquinoléine-4-carboxamides substitués pour thérapies antipaludéennes
EP2760862B1 (fr)	2011-09-27	2015-10-21	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
DK2787998T3 (en)	2011-12-06	2017-02-06	Sanofi Sa	Crystalline Forms of 2- (2-METHYLAMINOPYRIMIDIN-4-YL) -1H-INDOL-5-CARBOXYLIC ACID - [(S) -1-CARBAMOYL-2- (PHENYLPYRIMIDIN-2-YLAMINO) -ETHYL] -AMIDE
EA036521B1 (ru) *	2012-01-27	2020-11-19	Астразенека Аб	Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
KR101493877B1 (ko)	2013-03-29	2015-02-16	농업회사법인 주식회사 생명의나무	스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물
EP2805705B1 (fr)	2013-05-23	2016-11-09	IP Gesellschaft für Management mbH	Emballage comprenant des unités d'administration des sels de sodium de l'acide (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionique
EP2905282A1 (fr) *	2014-02-05	2015-08-12	AXXAM S.p.A.	Thiazole ou oxazole substituée en tant qu'antagonistes du récepteur P2X7
BR112016029044A2 (pt) *	2014-07-03	2017-08-22	Sanofi Sa	ácido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxílico [(s)-1-carbamoil-2-(fenil-pirimi¬din-2-il-amino)-etil]-amida para utilização no tratamento de dor associada à osteoartrite
US11007175B2 (en)	2015-01-06	2021-05-18	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
BR112017027656B1 (pt)	2015-06-22	2023-12-05	Arena Pharmaceuticals, Inc.	Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
EP3290416A1 (fr) *	2016-08-31	2018-03-07	AXXAM S.p.A.	Dérivés de n-[2-(4-phénoxypipéridin-1-yl)-2-(1,3-thiazol-5-yl)éthyl]benzamide et n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)éthyl]benzamide substitués et leur utilisation en tant qu'antagoniste du récepteur p2x7
CN106588803A (zh) *	2016-11-16	2017-04-26	西南科技大学	一种制备5‑乙酰基异噁唑的新方法
CN108299302A (zh) *	2017-01-11	2018-07-20	西南科技大学	一种制备3-乙酰基吡唑的新方法
CA3053418A1 (fr)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Composes et methodes de traitement de l'angiocholite biliaire primitive
BR112020024762A2 (pt)	2018-06-06	2021-03-23	Arena Pharmaceuticals, Inc.	métodos de tratamento de condições relacionadas ao receptor s1p1
MX2021011810A (es)	2019-03-29	2021-10-26	Astrazeneca Ab	Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
IL294527A (en) *	2020-01-30	2022-09-01	Anima Biotech Inc	Collagen-1 translation inhibitors and methods of their use
CN115974849B (zh) *	2022-12-28	2024-06-21	中国药科大学	一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0636623B1 (fr) *	1990-06-07	2001-08-16	AstraZeneca AB	Dérivés d'indole comme 5-HT1-like agonistes
CA2144763A1 (fr)	1992-10-14	1994-04-28	George D. Hartman	Antagonistes des recepteurs du fibrinogene
GB9225141D0 (en)	1992-12-01	1993-01-20	Smithkline Beecham Corp	Chemical compounds
IT1275433B (it) *	1995-05-19	1997-08-07	Smithkline Beecham Farma	Derivati di diarildiammine
FR2763337B1 (fr) *	1997-05-13	1999-08-20	Sanofi Sa	Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
SI1194425T1 (sl) *	1999-06-23	2005-12-31	Sanofi Aventis Deutschland	Substituirani benzimidazoli
DE19951360A1 (de) *	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
EP1363993A4 (fr)	2001-02-01	2008-11-12	Bristol Myers Squibb Co	Methodes de traitement de maladies inflammatoires et immunitaires a l'aide d'inhibiteurs d'i kappa b kinase (ikk)
DE10237723A1 (de) *	2002-08-17	2004-07-08	Aventis Pharma Deutschland Gmbh	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7462638B2 (en) *	2002-08-17	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7046741B2 (en) *	2004-04-16	2006-05-16	Data Flow Technologies, Inc.	Single and multiple sinewave modulation and demodulation techniques, apparatus, and communications systems

2002
- 2002-08-17 DE DE10237722A patent/DE10237722A1/de not_active Withdrawn
2003
- 2003-05-08 UA UAA200502387A patent/UA78591C2/uk unknown
- 2003-07-23 JO JO200387A patent/JO2764B1/en active
- 2003-08-05 SI SI200332173T patent/SI2233483T1/sl unknown
- 2003-08-05 PE PE2003000772A patent/PE20040893A1/es not_active Application Discontinuation
- 2003-08-05 ES ES03793685T patent/ES2358795T3/es not_active Expired - Lifetime
- 2003-08-05 PT PT10163200T patent/PT2233483E/pt unknown
- 2003-08-05 ES ES10163200T patent/ES2387954T3/es not_active Expired - Lifetime
- 2003-08-05 NZ NZ538296A patent/NZ538296A/en not_active IP Right Cessation
- 2003-08-05 SI SI200331971T patent/SI1530568T1/sl unknown
- 2003-08-05 KR KR1020057002707A patent/KR101162046B1/ko not_active Expired - Fee Related
- 2003-08-05 RU RU2005107418/04A patent/RU2318820C2/ru not_active IP Right Cessation
- 2003-08-05 DK DK10163200.8T patent/DK2233483T3/da active
- 2003-08-05 JP JP2004533319A patent/JP4504812B2/ja not_active Expired - Fee Related
- 2003-08-05 AT AT10163200T patent/ATE557018T1/de active
- 2003-08-05 EP EP10163200A patent/EP2233483B1/fr not_active Expired - Lifetime
- 2003-08-05 PL PL03374229A patent/PL374229A1/xx unknown
- 2003-08-05 OA OA1200500047A patent/OA12908A/en unknown
- 2003-08-05 DK DK03793685.3T patent/DK1530568T3/da active
- 2003-08-05 AT AT03793685T patent/ATE493402T1/de active
- 2003-08-05 ME MEP-606/08A patent/MEP60608A/xx unknown
- 2003-08-05 DE DE50313372T patent/DE50313372D1/de not_active Expired - Lifetime
- 2003-08-05 CA CA2498559A patent/CA2498559C/fr not_active Expired - Fee Related
- 2003-08-05 WO PCT/EP2003/008629 patent/WO2004022553A1/fr not_active Ceased
- 2003-08-05 HR HRP20050042AA patent/HRP20050042B1/hr not_active IP Right Cessation
- 2003-08-05 RS YU20050104A patent/RS51902B/sr unknown
- 2003-08-05 CN CNB038195437A patent/CN1314683C/zh not_active Expired - Fee Related
- 2003-08-05 BR BRPI0313562-4A patent/BR0313562A/pt not_active Application Discontinuation
- 2003-08-05 MX MXPA05001314A patent/MXPA05001314A/es active IP Right Grant
- 2003-08-05 AU AU2003263196A patent/AU2003263196B2/en not_active Ceased
- 2003-08-05 EP EP03793685A patent/EP1530568B1/fr not_active Expired - Lifetime
- 2003-08-05 PT PT03793685T patent/PT1530568E/pt unknown
- 2003-08-12 PA PA20038580501A patent/PA8580501A1/es unknown
- 2003-08-14 TW TW092122309A patent/TWI290552B/zh not_active IP Right Cessation
- 2003-08-14 AR ARP030102946A patent/AR040975A1/es not_active Application Discontinuation
- 2003-08-15 HN HN2003000249A patent/HN2003000249A/es unknown
- 2003-08-15 SV SV2003001599A patent/SV2004001599A/es unknown
- 2003-08-15 UY UY27941A patent/UY27941A1/es unknown
- 2003-08-15 MY MYPI20033115A patent/MY140074A/en unknown
- 2003-08-18 US US10/642,970 patent/US7285560B2/en not_active Expired - Lifetime
2005
- 2005-01-13 ZA ZA200500322A patent/ZA200500322B/en unknown
- 2005-01-28 CR CR7668A patent/CR7668A/es unknown
- 2005-02-09 IL IL16678505A patent/IL166785A0/xx not_active IP Right Cessation
- 2005-02-15 CO CO05013335A patent/CO5690586A2/es active IP Right Grant
- 2005-02-15 MA MA28106A patent/MA27382A1/fr unknown
- 2005-02-16 TN TNP2005000045A patent/TNSN05045A1/en unknown
- 2005-02-17 EC EC2005005612A patent/ECSP055612A/es unknown
- 2005-03-15 NO NO20051337A patent/NO330981B1/no not_active IP Right Cessation
2007
- 2007-06-06 US US11/758,978 patent/US8778955B2/en not_active Expired - Fee Related
2011
- 2011-03-02 CY CY20111100246T patent/CY1111692T1/el unknown
2012
- 2012-07-24 CY CY20121100658T patent/CY1112991T1/el unknown

Also Published As

Publication number	Publication date
PE20040893A1 (es)	2004-12-21
AU2003263196A1 (en)	2004-03-29
WO2004022553A1 (fr)	2004-03-18
HK1079509A1 (en)	2006-04-07
ATE493402T1 (de)	2011-01-15
PA8580501A1 (es)	2004-04-23
DK2233483T3 (da)	2012-08-20
ZA200500322B (en)	2006-07-26
IL166785A0 (en)	2006-01-15
TNSN05045A1 (en)	2007-05-14
CA2498559A1 (fr)	2004-03-18
KR20050058338A (ko)	2005-06-16
US7285560B2 (en)	2007-10-23
ES2358795T3 (es)	2011-05-13
SI2233483T1 (sl)	2012-08-31
RS51902B (sr)	2012-02-29
CR7668A (es)	2009-03-11
EP2233483A1 (fr)	2010-09-29
HRP20050042B1 (hr)	2013-09-30
RS20050104A (sr)	2007-06-04
EP1530568A1 (fr)	2005-05-18
UA78591C2 (en)	2007-04-10
CO5690586A2 (es)	2006-10-31
ATE557018T1 (de)	2012-05-15
RU2318820C2 (ru)	2008-03-10
CN1675196A (zh)	2005-09-28
CA2498559C (fr)	2012-01-24
HN2003000249A (es)	2008-08-06
PT1530568E (pt)	2011-02-23
CN1314683C (zh)	2007-05-09
TWI290552B (en)	2007-12-01
MXPA05001314A (es)	2005-04-28
ES2387954T3 (es)	2012-10-04
NO20051337L (no)	2005-05-03
PT2233483E (pt)	2012-07-20
JO2764B1 (en)	2014-03-15
SI1530568T1 (sl)	2011-05-31
DE10237722A1 (de)	2004-08-19
JP4504812B2 (ja)	2010-07-14
PL374229A1 (en)	2005-10-03
TW200418832A (en)	2004-10-01
AU2003263196B2 (en)	2009-01-22
ECSP055612A (es)	2005-04-18
AR040975A1 (es)	2005-04-27
EP1530568B1 (fr)	2010-12-29
MEP60608A (en)	2011-05-10
NZ538296A (en)	2007-03-30
OA12908A (en)	2006-10-13
SV2004001599A (es)	2004-02-26
DK1530568T3 (da)	2011-04-18
BR0313562A (pt)	2006-06-13
US8778955B2 (en)	2014-07-15
DE50313372D1 (de)	2011-02-10
CY1111692T1 (el)	2015-10-07
NO330981B1 (no)	2011-08-29
EP2233483B1 (fr)	2012-05-09
US20070244139A1 (en)	2007-10-18
HRP20050042A2 (en)	2006-03-31
KR101162046B1 (ko)	2012-07-04
UY27941A1 (es)	2004-03-31
US20050197353A1 (en)	2005-09-08
MY140074A (en)	2009-11-30
CY1112991T1 (el)	2016-04-13
JP2005539054A (ja)	2005-12-22
RU2005107418A (ru)	2005-08-27

Publication	Publication Date	Title
MA27382A1 (fr)	2005-06-01	DERIVES D'INDOLE OU DE BENZIMIDAZOLE POUR MODULER L'IkB KINASE
ZA200306335B (en)	2005-01-26	3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
MA27230A1 (fr)	2005-02-01	Derives d'aminoindazoles comme inhibiteurs de proteines-kinase
FR18C1024I2 (fr)	2019-05-17	Derives d'heterocyclocarboxamide
MA27083A1 (fr)	2004-12-20	Derives de nicotine ou d'isonicotine benzothiazole
NO20041604L (no)	2004-06-17	3-substituerte 4-pyrimidonderivater
MA26390A1 (fr)	2004-11-01	Derives d'acyl-4-carboxyphenyluree, procedes pour les preparer et leur utilisation
ATE316527T1 (de)	2006-02-15	Substituierte indolinone als tyrosinkinase inhibitoren
DK1412328T3 (da)	2007-02-12	Dolastatin-10-derivater
DE50014679D1 (de)	2007-11-08	Substituierte indol-mannichbasen
ATE308519T1 (de)	2005-11-15	2,3-substituierte indolverbindungen als cox-2 inhibitoren
NO20015737D0 (no)	2001-11-26	Indol derivater
IS6434A (is)	2002-06-19	Nýjar indól afleiður
PT1228041E (pt)	2004-02-27	Derivados de indol
NO20011892D0 (no)	2001-04-17	3-tetrahydropyridin-4-yl-indoler for behandling av psykotiske forstyrrelser
NO20031320D0 (no)	2003-03-21	System for klassifisering av havbunnsujevnhet
NO20026029L (no)	2002-12-16	Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO20035672D0 (no)	2003-12-18	Nye indolderivater
DOP2001000306A (es)	2002-12-15	Derivados de indol
DK1175397T3 (da)	2004-12-27	3,3-substituerede indolinderivater
FR2831398B1 (fr)	2004-03-12	Dispsoitif permettant de stopper automatiquement la combustion d'une cigarette
DK1305307T3 (da)	2004-08-09	Indolderivater
AU2002343329A1 (en)	2003-03-24	3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors